// App-Quantinova.ai

2973 : Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Researchers

Presenter

  • David J. Straus

Principal Investigators

  • Joseph M. Connors

  • rpd Ills

  • Marco Picardi

  • Ewa Lech-Maranda

  • Tatyana Feldman

  • Piotr Smolewski

  • Kerry J. Savage

  • Nancy L. Bartlett

  • Jan Walewski

  • Radhakrishnan Ramchandren

  • Pier Luigi Zinzani

  • Martin Hutchings

  • Javier Munoz

  • Won Seog Kim

  • Ranjana Advani

  • Stephen M. Ansell

  • Anas Younes

  • Andrea Gallamini

  • Rachael Liu

  • Meredith Little

  • Keenan Fenton

  • Michelle A. Fanale

  • John A. Radford

Medical Centers

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • BC Cancer Agency, Vancouver, BC, Canada

  • Institute of Internal Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary

  • Federico II University, Naples, Italy

  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa,

  • Hackensack University Medical Center, Oradell, NJ

  • Medical University of Lodz, Lodz, Poland

  • Centre for Lymphoid Cancer, Department of Medical Oncology, BC Cancer and The University of British Columbia, Vancouver, BC, Canada

  • Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

  • University of Tennessee Graduate School of Medicine, Knoxville, TN

  • Bologna University, Bologna, Italy

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Banner MD Anderson Cancer Center, Mesa, AZ

  • Samsung Medical Center, seoul, CA, Korea, Republic of (South)

  • Division of Oncology, Department of Medicine, Saul A. Rosenberg Professor of Lymphoma, Stanford Cancer Institute, Stanford, CA

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Antoine Lacassagne Center, Nice, France

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Seattle Genetics, Bothell, WA

  • Seattle Genetics, Bothell, WA

  • The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

Locations

  • United States

  • Poland

  • Canada

  • Hungary

  • Italy

  • Denmark

  • Republic of South Korea

  • France

  • United Kingdom

Companies

  • Millennium Pharmaceu

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

  • Peripheral neuropathy

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01712490

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved